Critical Updates in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Critical Updates in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Critical Updates in Treating Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
RestartResume

How can you improve treatment selection and decrease morbidity and mortality for your HABP/VABP patients?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Hospital-acquired and ventilator-associated bacterial pneumonia, or HABP and VABP, increase the risk of prolonged hospitalization, morbidity, and mortality for critically ill patients. Dr. Marin Kollef and Dr. Keith Kaye discuss the role of newer antimicrobials and novel agents in treating HABP/VABP.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host
    Keith S. Kaye, MD, MPH 
    Professor of Internal Medicine
    Director of Research, Division of Infectious Diseases
    University of Michigan Medical School
    Ann Arbor, MI 

    Consulting Fees: Allecra, Melinta, Merck, Nabriva, Shionogi, Tetraphase, Xellia
    Stock Ownership: Merck

    Faculty/Planner/Reviewer:
    Douglas N. Fish, PharmD
    Professor
    University of Colorado School of Pharmacy
    Aurora, CO

    Contracted Research: Merck

    Marin H. Kollef, MD, FACP, FCCP  
    Professor of Medicine, Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine
    Washington University School of Medicine
    St. Louis, MO

    Consulting Fees: Merck, Shionogi

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Douglas N. Fish, PharmD has disclosed contracted research from Merck.
    • Nick Lombardi has disclosed ownership interest in Vertex Pharmaceuticals.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients with Hospital-acquired bacterial or ventilator-associated bacterial pneumonia (HABP/VABP).  After participating in this educational activity, participants should be better able to:

    • Explain the key factors used to determine appropriate empiric therapy for patients with HABP/VABP
    • Develop optimal treatment plans for patients with HABP/VABP
  • Target Audience

    This activity is designed to meet the educational needs of infectious disease physicians, nurse practitioners, physician assistants, registered nurses, pharmacists and other members of the interprofessional team who are involved in the management of patients with hospital-acquired bacterial or ventilator-associated bacterial pneumonia (HABP/VABP).

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Postgraduate Institute for Medicine (PIM). GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Joint Accreditation Statement 
    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Learning Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Pharmacy Education
    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-20-2299-H01-P)

    Type of Activity: Application

    Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.    

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free